Molecular imaging of epidermal growth factor receptor expression-activity at the kinase level in tumors with positron...

Area of Science:

• Oncology
• Radiochemistry
• Molecular Imaging

Background:

• The epidermal growth factor receptor (EGFR) signaling pathway is crucial in various cancers.
• Targeted therapies inhibiting EGFR are vital for cancer treatment.
• Non-invasive imaging is needed for selecting and monitoring these therapies.

Purpose of the Study:

• To explore the development of novel positron emission tomography (PET) imaging agents for EGFR.
• To investigate EGFR-tyrosine kinase inhibitors as potential radiotracers.
• To enable precise patient stratification for EGFR-targeted therapies.

Main Methods:

• Review of EGFR-tyrosine kinase inhibitors as radiotracers.
• Focus on anilinoquinazoline pharmacophore for PET agent development.
• Exploration of I-124, F-18, and C-11 labeled irreversible EGFR inhibitors.

Main Results:

• Anilinoquinazoline derivatives show promise as EGFR imaging agents.
• Radiolabeled irreversible EGFR inhibitors are suitable for PET imaging.
• Development of agents targeting activated EGFR kinase is feasible.

Conclusions:

• PET imaging agents targeting EGFR tyrosine kinase can guide patient selection for EGFR inhibitors.
• Non-invasive monitoring of EGFR-targeted therapy response is achievable.
• Targeting activated EGFR kinase with PET facilitates personalized cancer treatment.